For sixty years, the answer to childhood leukemia has been the same answer, intensified: more chemotherapy, given earlier, with the side effects accepted as the price of survival. A trial published today asks what happens when you run the experiment in reverse, removing chemotherapy instead of adding it, and the result is the kind of finding that changes treatment guidelines.
The AIEOP-BFM ALL 2017 trial, published in the New England Journal of Medicine, followed 709 children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia across more than 100 centers in eight countries. Half received the standard regimen, two intensive blocks of chemotherapy. The other half received two cycles of blinatumomab, an immunotherapy that links the body's own T cells to leukemia cells so the immune system destroys them. After four years, the immunotherapy group had fewer relapses and far fewer severe complications. The trial did not add immunotherapy to chemotherapy. It replaced the chemotherapy.
What the numbers show
Four-year event-free survival, the measure that counts survival without relapse, second cancers, or death, was 83.0 percent in the blinatumomab group against 70.3 percent in the chemotherapy group. The hazard ratio of 0.51 means the risk of a relapse or death event was roughly halved, a difference that would be notable in adults and is striking in a disease where the baseline cure rate is already high.
The side-effect numbers are the second half of the finding, and for families they may be the more meaningful half. Treatment-related infections fell from 69.4 percent in the chemotherapy arm to 23.9 percent in the immunotherapy arm. Chemotherapy for high-risk leukemia suppresses the immune system so thoroughly that infection is not a complication of treatment but a routine part of it. Cutting the infection rate by two thirds is what a better treatment feels like on a children's ward: fewer fevers, fewer emergency antibiotics, fewer intensive care admissions.
The trial was led by the ALL-BFM study center at the University Hospital Schleswig-Holstein in Kiel and funded by Deutsche Krebshilfe, Germany's largest cancer charity. The researchers used the word "breakthrough" in their announcement, and the structure of the finding justifies it. Every prior immunotherapy advance in this disease added the drug to chemotherapy. This is the first demonstration that immunotherapy can replace part of it.
Why replacement matters more than addition
The distinction between adding and replacing is the whole story. Adding a drug always increases toxicity; the question is only whether the survival gain is worth the extra harm. Replacing a toxic block with a less toxic one can improve survival and reduce harm at the same time, which is what happened here. The children on the immunotherapy arm got less of the most toxic part of their treatment and did better.
There is a deeper significance for how pediatric oncology thinks. The field's history is one of escalation, pushing chemotherapy intensity up against the limits of what children can survive, because that is what saved them. Blinatumomab offers de-escalation without loss of cure, the first credible exit from the escalation logic. The trial's sponsors are already planning a follow-up study to test whether immunotherapy can replace chemotherapy in additional patient groups, and the direction of travel in the field is now unmistakable.
The disease this matters for
Acute lymphoblastic leukemia is the most common childhood cancer. About 90 percent of children with ALL are cured with intensive chemotherapy, which sounds like a solved problem until you look at who is not in that 90 percent. Roughly one in five children is classified as high risk, and it is these children who receive the most toxic chemotherapy and who account for most of the relapses that do occur. The trial enrolled exactly this group, the children for whom the standard regimen was both the most dangerous and the most likely to fail.
For a high-risk child, a relapse usually means the disease returns harder to treat, and the options narrow toward transplant or newer therapies with their own risks. The 83 percent event-free survival in the immunotherapy arm is not a cure rate, and it should not be read as one. Some children in the trial still relapsed. What the number shows is a meaningfully better outcome than the current standard, achieved with meaningfully less harm, which is the definition of progress in this disease.
The 24 percent infection rate is also not zero, and blinatumomab has its own known effects that the trial's design already accounts for in clinical practice. The honest reading of the trial is not that the hard parts of treating high-risk leukemia are over. It is that the field now has evidence that one of the hardest parts, the intensive chemotherapy blocks, can be replaced by something both safer and more effective. That is a rare combination in cancer medicine.
The drug's own history explains the finding
Blinatumomab is not new. The bispecific antibody has been approved for nearly a dozen years, first for relapsed or refractory B-cell ALL, then for patients with measurable residual disease after initial treatment. Its mechanism, a bispecific T-cell engager that holds a T cell and a leukemia cell together until the T cell kills the leukemia cell, has been understood since the early trials. What the drug had never been tested for, until now, was first-line replacement: giving it instead of chemotherapy to newly diagnosed children, before the disease has ever relapsed.
The distinction between the drug's prior uses and this trial is the difference between rescue and prevention. In the relapse setting, blinatumomab treats children whose disease has already proven itself resistant. In this trial, it faced the disease's first appearance, at its most treatable moment, and it outperformed the standard. The result suggests the drug's reputation as a salvage therapy undersold it; the same mechanism that rescues relapsed children appears to prevent relapses when used up front.
There is also an instructive contrast with the other major blinatumomab trial in children, the AALL1731 study, which added blinatumomab to standard chemotherapy in lower-risk patients. That trial improved disease-free survival too, but a 2026 review noted the sepsis rate rose from 5.1 percent to 14.8 percent when the drug was stacked on top of chemotherapy. Add immunotherapy to chemotherapy and the toxicity stacks as well. Replace the chemotherapy and the infections fall by two thirds. The two trials, read together, make the case for the replacement strategy more clearly than either makes alone.
The trial's limits, stated plainly
A finding this good deserves its boundaries stated as clearly as its results. The trial's follow-up runs to four years, which is meaningful for a disease whose relapses cluster in the first years after diagnosis but not yet the decade-scale view that pediatric oncology ultimately demands. The event-free survival curves may converge, hold, or separate further with time, and the late-effects picture, the second cancers and organ damage that follow survivors for decades, is still forming.
The study also did not test immunotherapy alone against all chemotherapy. The replacement covered two specific chemotherapy blocks in a larger treatment framework; the children still received other chemotherapy elements, and the question of how much chemotherapy can ultimately be removed remains open. The planned follow-up study aims at additional patient groups, which is the field acknowledging that this trial is the first step of a de-escalation program, not its endpoint.
For parents, the translation is careful but real. The evidence now supports a regimen that is both more effective and less toxic for the highest-risk children, in a disease where the previous tradeoff was brutal in both directions. That is not a cure, and no honest reading makes it one. It is the strongest evidence yet that the next decade of childhood leukemia treatment will involve less chemotherapy, not more, and the children in this trial are the first cohort to show it can be done without giving anything up.
What happens next
The trial's results will now travel the usual route: into treatment guidelines, into national protocol reviews, and into the next generation of trials that ask how much chemotherapy can be replaced and in which patients. The follow-up study planned to start later this year will extend the question to additional groups, and the protocol committees in Europe and North America that run pediatric leukemia trials will weigh whether the replacement regimen becomes the new standard arm.
For families facing a new diagnosis, the practical meaning is specific. Blinatumomab is an existing drug, approved for certain forms of B-cell leukemia, and the trial's regimen is the kind of change that can reach treatment protocols relatively quickly once the guideline groups act. No parent should leave this article thinking the new treatment is available everywhere tomorrow, and no parent should think the current standard is obsolete today. What changed today is the evidence, and the evidence now says the hardest part of treatment may not be necessary, for a specific group of children, in exchange for a better outcome. The guidelines will catch up to that, and the history of this disease says they will do it quickly.
Primary sources
- New England Journal of Medicine for the trial publication, the 709-child cohort, the event-free survival and infection figures, and the hazard ratio.
- UKSH Kiel press release for the trial design, funding, and the replacement-versus-addition framing.
- idw-online for the German clinical context and the follow-up study plans.